PFPP re-introduces DMPA.
The Philippine Family Planning Program formally re-introduced depomedroxyprogesterone acetate (DMPA) or DepoProvera as a program method last March 22, 1994.  DMPA will be added to the choices available to couples who desire to practice responsible parenthood. DMPA is an injectable contraceptive containing synthetic progestin which resembles progesterone.  It is a scientifically effective, medically safe and legal contraceptive which is injected every three months.  Its effectivity reaches up to 99.7% in the first year of use.  A WHO [World Health Organization] study had shown that its effectiveness is comparable to bilateral tubal ligation.  DMPA's mechanism of action is the inhibition of ovulation and the thinning of the endometrium. It is a safe contraceptive which the US Drug and Food Authority (USDFA) and our own Bureau of Food and Drug Authority had approved for contraceptive use.  WHO studies had shown that DMPA does not lead to increased cancer risk, congenital malformation and infertility.  DMPA was initially developed in the 1960s as a treatment for endometrial and renal cancer.  Its contraceptive effects then led to its use as a family planning method.  Over 9 million women had used DMPA.  It is a very safe, reversible and effective family planning method with manageable side effects. These include:  menstrual irregularities, amenorrhea, weight gain, nausea and vomiting.  These effects can be adequately managed by a trained service provider.  DMPA will be initially introduced by the Department of Health in 10 pilot areas.  IMCH will soon introduce the method in our clinics once the supplies are available and the clinic staff are prepared in the service provision of DMPA.
D001208:Asia; D001210:Asia, Southeastern; D003257:Consumer Product Safety; D003267:Contraception; D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003906:Developing Countries; D005193:Family Planning Services; D006285:Health Planning; D007878:Legislation as Topic; D017258:Medroxyprogesterone Acetate; D010679:Philippines
D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D017258:Medroxyprogesterone Acetate
Asia; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Depo-provera; Developing Countries; Family Planning; Family Planning Programs; Legislation; Medroxyprogesterone Acetate; Philippines; Product Approval; Southeastern Asia